TABLE 3.

Univariate Cox regression analysis of clinical and laboratory parameters associated with the overall survival of non‐small cell lung cancer patients treated with immune checkpoint inhibitors.

Parameters	Category	Hazard ratios	95% CI of HR	p‐value
ECOG PS	2–4	1.85	1.02–3.40	0.045
	0–1	Reference
Age	≥75	0.97	0.62–1.50	0.9
	<75	Reference
Sex	Female	1.09	0.87–1.35	0.5
	Male	Reference
Stage	Recurrence	0.65	0.36–1.18	0.2
	III	0.72	0.44–1.16	0.2
	IV	Reference
Histological type	Sq	1.15	0.75–1.66	0.6
	Non‐Sq	Reference
Liver metastasis	Yes	1.95	1.04–3.65	0.04
	No	Reference
Brain metastasis	Yes	1.34	0.87–2.05	0.20
	No	Reference
Eosinophils	<100/μL	0.50	0.22–1.12	0.09
	≤100/μL, <500/μL	0.30	0.14–0.66	0.003
	≥500/μL	Reference
Increased REC	Yes	0.49	0.34–0.71	<0.001
	Νο	Reference
Increased RNC	Yes	1.98	1.07–3.65	0.03
	Νο	Reference
Increased RLC	Yes	0.54	0.37–0.79	0.001
	Νο	Reference
sNLR, ratio	<5	1.08	0.65–1.78	0.8
	≥5	Reference
CRP	≥1 mg/dL	1.49	1.03–2.15	0.04
	<1 mg/dL	Reference
Alb	≥3.5 g/dL	0.68	0.47–0.999	0.049
	<3.5 g/dL	Reference
Tumor size	≥5 cm	1.81	1.24–2.64	0.002
	<5 cm	Reference
PD‐L1	≥1%	0.67	0.43–1.03	0.07
	<1%	Reference

Abbreviations: Alb, albumin; CI, confidence interval; CRP, C‐reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; Non‐Sq, nonsquamous cell carcinoma; PD‐L1, programmed death ligand 1; REC, relative eosinophil count; RLC, relative lymphocyte count; RNC, relative neutrophil count; sNLR, neutrophil‐to‐lymphocyte ratio in serum; Sq, squamous cell carcinoma.